丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

PRELIMINARY ANNUAL RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2020

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined by the provisions of Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571) of the Laws of Hong Kong by Livzon Pharmaceutical Group Inc.* 麗珠醫藥集團股份有限公司 (the "Company", together with its subsidiaries, the "Group").

The Company and all members of the board of directors guarantee that the information stated in this announcement is true, accurate and complete and does not contain any false representation, misleading statement or material omission.

Important: The financial data for the six months ended 30 June 2020 set out in this announcement represents figures of preliminary estimations only and has not been audited by an auditing firm. As a result, differences may be found between the data below and the definitive financial data disclosed in the 2020 Interim Report. Investors are advised to be cautious about investment risks involved.

I. PRELIMINARY RESULTS FOR THE PERIOD

1. Period for the preliminary estimated results：1 January 2020 to 30 June 2020
2. Preliminary estimated operating results：Increase over the corresponding period last year

Item	Current reporting period	Corresponding period last year
Net profit attributable to the shareholders of the listed company	Profit: approximately RMB960.6321 million – RMB1,034.5269 million	Profit: RMB738.9478 million
	Increased by approximately 30.00% – 40.00% as compared to the corresponding period last year	
Net profit attributable to the shareholders of the listed company after deducting the extraordinary gain or loss	Profit: approximately RMB790.3184 million – RMB856.1782 million	Profit: RMB658.5986 million
	Increased by approximately 20.00% – 30.00% as compared to the corresponding period last year	
Basic earnings per share (RMB/share)	Profit: approximately RMB1.02 – RMB1.10 per share	Profit: RMB0.79 per share

Note: In July 2019, as a result of the implementation of conversion of capital reserve by the Company, earnings per share for the corresponding period last year has been adjusted in accordance with the requirement of applicable accounting standards.

II. AUDIT STATUS OF THE PRELIMINARY ESTIMATED RESULTS

The preliminary estimated results have not been audited by certified public accountants.

III. EXPLANATION FOR THE CHANGES IN RESULTS

The results of the Company for the six months ended 30 June 2020 have increased as compared to the corresponding period last year, which were mainly attributable to:

1. The net profit of the Company attributable to the parent company will increase by approximately RMB85.2399 million as a result of the disposal of equity interest in Jiangsu Ni Ke Medical Device Co., Ltd. (江蘇尼科醫療器械有限公司).

2. During the first half of 2020, the sales of the Company's products relating to prescription medicines did not reach the expected level due to the impact of the COVID-19 outbreak. Nevertheless, a substantial increase in the sales of Anti-viral Granules (抗病毒顆粒) and Ilaprazole Sodium for Injection (注射用艾普拉唑鈉) as compared with that during the first half of the previous year together with additional product sales of diagnostics kit for antibody to novel coronavirus provided important support to the overall growth in the Company's performance.

IV. OTHER RELEVANT INFORMATION

1. Figures related to these preliminary estimated results are arrived based on the estimated calculation of the Company, and have not been audited by an auditing firm;

2. Detailed financial information will be disclosed in the 2020 Interim Report of the Company. Potential investors are advised to pay attention to the risks associated with the investment.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc.*
Yang Liang
Company Secretary

Zhuhai, China
14 July 2020

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.

** For identification purpose only*